Focused Alpha LLC’s United Therapeutics UTHR Stock Holding History

Focused Alpha LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$538K	Buy	+992	New	+$513K	0.13%	142

Other funds holding UTHR

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Focused Alpha LLC's UTHR Position: Q3 2026 in Review

Focused Alpha LLC opened a new position in United Therapeutics (UTHR) in Q3 2026: 992 shares worth $538K. The stake represents 0.13% of the portfolio and ranks #142 among its holdings.

128 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

Focused Alpha LLC held 992 shares of United Therapeutics worth $538K as of Q3 2026.
United Therapeutics was a new Focused Alpha LLC position in Q3 2026.
United Therapeutics made up 0.13% of Focused Alpha LLC's portfolio in Q3 2026, its #142 holding.
128 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Focused Alpha LLC's 13F filing for Q3 2026, filed 20 Oct 2026.